Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome.

Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U.

J Oncol Pract. 2012 May;8(3 Suppl):e24s-30s. doi: 10.1200/JOP.2011.000535.

2.

Influence of patient preferences on the cost-effectiveness of screening for Lynch syndrome.

Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum U.

Am J Manag Care. 2012 May 1;18(5):e179-85.

3.

Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA.

Ann Intern Med. 2011 Jul 19;155(2):69-79. doi: 10.7326/0003-4819-155-2-201107190-00002.

4.

A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.

Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C.

BMC Cancer. 2015 Apr 25;15:313. doi: 10.1186/s12885-015-1254-5.

5.

A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.

Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C.

Health Technol Assess. 2014 Sep;18(58):1-406. doi: 10.3310/hta18580. Review.

6.

Comparative effectiveness of screening strategies for Lynch syndrome.

Barzi A, Sadeghi S, Kattan MW, Meropol NJ.

J Natl Cancer Inst. 2015 Mar 20;107(4). pii: djv005. doi: 10.1093/jnci/djv005. Print 2015 Apr.

7.

The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Mvundura M, Grosse SD, Hampel H, Palomaki GE.

Genet Med. 2010 Feb;12(2):93-104. doi: 10.1097/GIM.0b013e3181cd666c.

PMID:
20084010
9.

Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.

Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.

Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.

10.

Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome.

Kuppermann M, Wang G, Wong S, Blanco A, Conrad P, Nakagawa S, Terdiman J, Ladabaum U.

Cancer. 2013 Jan 1;119(1):215-25. doi: 10.1002/cncr.27634. Epub 2012 Jul 11.

11.

Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.

Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1158-66. doi: 10.1016/j.cgh.2013.03.013. Epub 2013 Mar 28.

PMID:
23542330
12.

Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome.

Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH.

Cancer. 2008 Jul 15;113(2):326-35. doi: 10.1002/cncr.23554.

13.

Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.

Ferguson SE, Aronson M, Pollett A, Eiriksson LR, Oza AM, Gallinger S, Lerner-Ellis J, Alvandi Z, Bernardini MQ, MacKay HJ, Mojtahedi G, Tone AA, Massey C, Clarke BA.

Cancer. 2014 Dec 15;120(24):3932-9. doi: 10.1002/cncr.28933. Epub 2014 Jul 31.

14.

Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review.

Sharaf RN, Myer P, Stave CD, Diamond LC, Ladabaum U.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1093-100. doi: 10.1016/j.cgh.2013.04.044. Epub 2013 May 10. Review.

PMID:
23669308
15.

Identification of Lynch syndrome among patients with colorectal cancer.

Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, Haile R, Thibodeau SN, Gunawardena S, Jenkins MA, Buchanan DD, Potter JD, Baron JA, Ahnen DJ, Moreno V, Andreu M, Ponz de Leon M, Rustgi AK, Castells A; EPICOLON Consortium.

JAMA. 2012 Oct 17;308(15):1555-65. doi: 10.1001/jama.2012.13088.

16.

Population-based molecular screening for Lynch syndrome: implications for personalized medicine.

Ward RL, Hicks S, Hawkins NJ.

J Clin Oncol. 2013 Jul 10;31(20):2554-62. doi: 10.1200/JCO.2012.46.8454. Epub 2013 Jun 3. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

PMID:
23733757
17.

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA.

Ann Intern Med. 1999 Jan 19;130(2):97-107.

PMID:
10068381
18.

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.

Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry KU, Krämer A, Siebert U.

GMS Health Technol Assess. 2010 Apr 27;6:Doc05. doi: 10.3205/hta000083.

19.

Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients.

Resnick K, Straughn JM Jr, Backes F, Hampel H, Matthews KS, Cohn DE.

Obstet Gynecol. 2009 Sep;114(3):530-6. doi: 10.1097/AOG.0b013e3181b11ecc.

PMID:
19701031
20.

A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial.

Roth RM, Hampel H, Arnold CA, Yearsley MM, Marsh WL, Frankel WL.

Am J Clin Pathol. 2015 Mar;143(3):336-43. doi: 10.1309/AJCP4D7RXOBHLKGJ.

PMID:
25696791

Supplemental Content

Support Center